BioSpace News Archive

Dr. Hernandez has spent the last 8 years working on the design, development, and optimization of breast CT at the University of California, Davis, where he has worked under the mentorship of Dr. John M. Boone, Principal breast CT Founder and Company Director.

Cyclacel Pharmaceuticals, Inc. announced dosing of the first patient in the Company’s multi-cohort Phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes (MDS).

I-MED Pharma USA is bringing the world’s most innovative dry eye product portfolio to the U.S. market.

Medtronic plc, a global leader in healthcare technology, unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation Trial, which was presented as a Late Breaking Clinical Trial at the 33rd Transcatheter Cardiovascular Therapeutics conference, the annual scientific symposium of the Cardiovascular Research Foundation.

Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost.

TFF Pharmaceuticals, Inc. today announced that it will release its financial results and business update for the third quarter of 2021 on Monday, November 15, 2021, at the close of the U.S. financial markets.

Castle Biosciences, Inc today announced the publication of a study validating performance of a novel algorithm designed to integrate the DecisionDx®-Melanoma gene expression profile

Alnylam Pharmaceuticals, Inc. announced today positive results from the 6-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1

Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, announced that the Company will release financial results for the third quarter ended September 30, 2021 on Wednesday, November 10, 2021, after the market close.

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from the Phase III ASCEND (Anaemia Studies in Chronic Kidney Disease: